~~<i id='76A2E65CBC'><strike id='76A2E65CBC'><tt id='76A2E65CBC'><pre id='76A2E65CBC'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：focus 2025-09-05 11:32:20 - browse：89

The Food and Drug Administration on Thursday approved a gene therapy to treat people with hemophilia A, an inherited and rare bleeding disorder.

The treatment, called Roctavian, is made by BioMarin Pharmaceutical. It was first approved in Europe in August 2022.

Roctavian is a one-time therapy that, in clinical trials, dramatically reduced bleeding episodes and helped patients live without the blood transfusions used to treat the disease. The FDA first rejected Roctavian in 2020, asking BioMarin to amass more data on its safety and long-term durability, and then delayed its decision again to account for additional evidence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： Readout Newsletter: Amylyx, Aurinia, and IQVIA

knowledge

hotspot

knowledge

hotspot

focus

AdobeIfthepastyearwasprelude,theU.S.governmentin2024ispoisedtore-writetherulessurroundingtheuseofart

WSS

Ultragenyx gene therapy for rare liver ailment succeeds in late

Report cites 'urgent' need to recruit more diverse clinical trial participants

At ASCO, pharma leaders speak of advances in 'smart bomb' drugs

BMI, flaws aside, is found to be useful estimate of body fat in youth

Latigo launches with $135 million for Vertex

Why Eli Lilly’s earnings didn’t quite live up to the hype

knowledge

hotspot

knowledge

Bright Health sells Medicare Advantage business to Molina

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Wildfire smoke exposes gaps in outdoor worker protections

NIH documents show early flaws of $1.6 billion long Covid program

State Dept. review finds Biden bears some blame for Afghanistan failures

Why don't Americans have at

Cancer drug shortages should be causing more outrage

Doctors on social media are being harassed and cyberbullied

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The Pandemic Treaty must support building strong health systems

hotspot

At ASCO, AstraZeneca reports strong data for breast cancer drug

Congress must protect the remaining independent doctors

Intellia reports positive results for its CRISPR

Eli Lilly reports tirzepatide MASH success during Q4 earnings

Ionis drug prevents swelling attacks due to hereditary angioedema

Lilly to acquire Dermira for $1.1 billion, adding eczema drug to its pipeline

knowledge

hotspot

focus

focus